
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is positioned for a favorable outlook due to its innovative antibody-based therapies, particularly PEMGARDA, which has demonstrated enduring efficacy against currently dominant SARS-CoV-2 variants, including LP.8.1, XEC, and KP.3.1.1. The company's focus on high-risk populations, specifically immunocompromised individuals, highlights a strategic approach to capture a significant market segment, especially as the demand for effective pre-exposure prevention continues to rise. Additionally, positive Phase 3 data and the anticipation of improved launch trajectories in 2025 further underscore the potential for revenue growth, driven by robust clinical evidence and the ongoing development of advanced candidates like VYD2311.
Bears say
Invivyd Inc faces significant regulatory challenges that have negatively impacted its stock outlook, particularly highlighted by the FDA's rejection of the company's request to expand the Emergency Use Authorization (EUA) of its treatment PEMGARDA for mild-to-moderate COVID-19. This setback emphasizes the difficulties in securing approvals for COVID-19 therapeutics, suggesting that a lack of diversification in the company's pipeline may hinder its long-term growth potential. Furthermore, the decision leaves a vulnerable patient population without access to effective monoclonal antibody treatments, raising concerns about the company's ability to generate revenues and maintain investor confidence.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares